Inspire Medical Systems Inc (INSP.NYSE) AI OPINIONS & ADVISOR ANALYSIS

The bull case activates when the realized professional-fee cut lands near 10% rather than 50%. Surgeons resume implanting, volumes inflect in 2027 rather than 2028, and 85.5% gross margins convert modest volume recovery into disproportionate operating income. Positive earnings revisions then pull a Hold-heavy sell-side toward upgrades, while the net-cash position funds aggressive buybacks into a still-depressed 28.9 million-share float. Growth restored plus multiple repair compounds; the stock materially outruns the base path.

The bear case activates if the professional-fee reduction settles near the 50% ceiling and Nyxoah's reimbursement uplift converts into real share. Surgeons redirect cases, Inspire's fixed commercial cost base deleverages against falling revenue, and cash burn replaces the $117 million trailing free cash flow. GLP-1 utilization management then narrows the funnel structurally, so the 2028 code repair arrives to a smaller market. The equity re-rates toward net cash plus a modest franchise value.

The settled belief: a broken single-product compounder whose coding problem is unmodellable, so wait for 2028. Twelve of sixteen recent ratings are Hold with an average target of $68.19 — below the anchor price [17]. The anchoring bias is the 73% three-year drawdown [19]; investors treat a dated, reversible billing defect as permanent demand destruction, while celebrating guidance that still implies a revenue decline.

The crowd modestly underestimates these shares, implying underpricing — but the easy portion is already paid for after roughly an 80% rally off the June low of $42.61 [20]. The overlooked evidence is causal, not sentimental: revenue fell because Inspire's own sensor-less redesign triggered a -52 modifier on the surgeon's fee [6], while that identical redesign lifted gross margin to 85.5% [10]. Markets price demand destruction; the filings document a reimbursement mechanic with a dated repair path.

The decisive trigger is the Medicare Physician Fee Schedule final rule around November 2027, publishing RVUs for the new hypoglossal Category I code effective January 2028. Quantified fee restoration converts an unmodellable range into a number. First observable sign: FY2028 revenue guidance returning to growth.